Search Saint Luke's

Julie Quirin, President of BJC’s West region, which consists of Saint Luke’s, and Chris Watts, BJC Chief Strategy Officer, talk with the Kansas City Business Journal about the early days of the integration, the potential benefit they see for patients and the communities we serve, and what the future may hold.

The Kansas City Business Journal named Bobby Olm-Shipman, CEO of Saint Luke's South and East Region, as one of its 20 health care professionals to know in the Kansas City area for 2024.

After a devastating heart attack and spinal cord stroke left him unable to move his legs, Adrian's persistence with rehabilitation made it possible for him to get a life-saving heart transplant.

When John Murray was losing function in his hands and arms, it became difficult to play his music. He turned to the team at Saint Luke's Marion Bloch Neuroscience Institute to fix the issue threatening his independent lifestyle.

Kansas City Orthopaedic Institute (KCOI), a physician-owned hospital, is the first and only hospital in the Kansas City area dedicated solely to orthopedics. KCOI was created through a strategic alliance between leading orthopedic surgeons and Saint Luke’s Health System.

Kansas City is poised to become a national leader in addressing the nation’s maternal health crisis, and there’s a way for you to help or to be treated if you’re pregnant and have a heart condition.

Chris Alldaffer’s symptoms began on Dec. 22. It felt like run-of-the-mill flu. Sore body. Scratchy throat. Stiff neck. But his symptoms ramped up daily, and by Christmas day he was in a local emergency room with an unrelenting temperature that kept spiking at 105.

The Kansas City Star talked to Bobby Olm-Shipman about the new services and additions patients can expect to see once the project is completed.

Representatives of Saint Luke’s and others came together to urge the Kansas Legislature to approve a bill creating new crimes of interfering with a health care worker.

Breast Cancer
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy